MAGE-C1 Antibodies

Santa Cruz Biotechnology provides a broad selection of MAGE-C1 monoclonal antibodies for research focused on this important cancer/testis antigen. MAGE-C1 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). MAGE-C1, a member of the MAGE family, is primarily expressed in testicular germ cells and certain tumors, making it a significant target for cancer immunotherapy. Expression patterns in malignant tissues, coupled with minimal presence in normal somatic tissues, establish MAGE-C1 as a valuable biomarker for cancer diagnosis and treatment. Research into MAGE-C1 continues to reveal important mechanisms in tumorigenesis. Understanding MAGE-C1 expression and regulation provides critical insights for developing targeted cancer therapies. Investigating MAGE-C1 functionality helps identify new therapeutic approaches and potential treatment strategies. MAGE-C1 research using Santa Cruz Biotechnology monoclonal antibodies enables scientists to make meaningful contributions to cancer research and therapeutic development.